US President, Joe Biden, has urged Americans not to panic about the new COVID-19 Omicron variant and said the United States was making contingency plans with pharmaceutical companies if new vaccines are needed, Reuters news agency reported on Tuesday.
Biden said the country would not go back to lockdowns to stop the spread of the Omicron variant and that he would lay out his strategy on Thursday for combating the pandemic over the winter.
The president said in remarks at the White House following a meeting with his COVID-19 team: "This variant is a cause for concern, not a cause for panic. We're going to fight and beat this new variant."
He also urged people to get vaccinated, get boosters and wear masks adding that it was inevitable that Omicron cases would emerge in the United States.
While Biden said he believed that existing vaccines would continue to protect against severe disease, he added that his administration was working with vaccine makers Pfizer (NYSE:PFE), Moderna (Nasdaq:MRNA) and Johnson & Johnson (NYSE:JNJ) to develop contingency plans.
President Biden also said he would direct the US Food and Drug Administration and the Centres for Disease Control and Prevention (CDC) to make those vaccines available quickly.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval